Compare ASRV & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASRV | IMMP |
|---|---|---|
| Founded | 1983 | 1987 |
| Country | United States | Australia |
| Employees | 298 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.9M | 58.2M |
| IPO Year | 1994 | 2012 |
| Metric | ASRV | IMMP |
|---|---|---|
| Price | $3.66 | $0.45 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 10.7K | ★ 21.8M |
| Earning Date | 04-21-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | ★ 61.90 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $14,634,000.00 | N/A |
| Revenue This Year | N/A | $445.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.92 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.48 | $0.29 |
| 52 Week High | $4.04 | $3.53 |
| Indicator | ASRV | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 44.45 | 33.72 |
| Support Level | $3.62 | $0.29 |
| Resistance Level | $3.96 | $1.05 |
| Average True Range (ATR) | 0.16 | 0.03 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 25.00 | 14.24 |
AmeriServ Financial Inc is a bank holding company. The company and its subsidiaries derive substantially all of their income from banking, bank-related services, and trust-related services. Its operating segment includes community banking and it generates maximum revenue. The community banking segment includes both retail and commercial banking activities. The company also offers retail banking which includes the deposit-gathering branch franchise and lending to both individuals and small businesses; Lending activities include residential mortgage loans, direct consumer loans, and small business commercial loans; Commercial banking to businesses includes commercial loans, business services, and CRE loans.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.